Dr. Marjorie Zauderer, MD – New York, NY
Daniel Moore
Updated on January 11, 2026
Overview of Dr. Zauderer
Dr. Marjorie Zauderer is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 11 years. Dr. Zauderer accepts several types of health insurance, listed below. She is one of 468 doctors at Memorial Sloan-Kettering Cancer Center who specialize in Oncology. She has more than 80 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2006 - 2009
Columbia University Vagelos College of Physicians and SurgeonsClass of 2006
Certifications & Licensure
FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NY State Medical License 2007 - 2025
NJ State Medical License 2019 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
Sato, H., Ito, T., Hayashi, T., Kitano, S., Erdjument-Bromage, H., Toyooka, S., Bott, M., Zauderer, M., Ladanyi, M.> ;Oncogene. 2024 Feb 21Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
Szlosarek, P., Creelan, B., Sarkodie, T., Nolan, L., Taylor, P., Olevsky, O., Grosso, F., Cortinovis, D., Chitnis, M., Roy, A., Gilligan, D., Kindler, H., Papadatos-Pa...> ;JAMA Oncology. 2024 Feb 15Response letter to "Stereotactic body radiation therapy for pleural mesothelioma: Which goal, which patients".
Simone, C., Shin, J., Offin, M., Shepherd, A., Wu, A., Shaverdian, N., Gelblum, D., Gomez, D., Sauter, J., Ginsberg, M., Adusumilli, P., Rusch, V., Zauderer, M., Rimne...> ;Radiotherapy and Oncology. 2024 Feb 10- Join now to see all
Lectures
Association of BAP1 alterations with malignant pleural mesothelioma treated with trimodality therapy.
2019 ASCO Annual Meeting - 6/1/2019Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactiva...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
MSK Research Highlights, November 23, 2022November 23rd, 2022
MARF to Host International Symposium on Malignant MesotheliomaJuly 20th, 2022
‘Promising’ Durvalumab Results Spark Phase 3 Trial in MesotheliomaJune 4th, 2020
- Join now to see all
